Molecular targeted therapies in head and neck cancer--an update of recent developments-.
Molecular targeted therapies in head and neck cancer--an update of recent developments-.
复制标题
DOI：
10.1186/1758-3284-2-8
复制
发表时间：
2010-04-14
期刊：
影响因子：
--
通讯作者：
Sudhoff H
中科院分区：
文献类型：
--
作者：
Goerner M;Seiwert TY;Sudhoff H
在过去的十年中，靶向治疗已经进入临床实践。它们在临床肿瘤学和血液学的许多领域对癌症患者的生存产生了重大影响。事实上，在一些血液恶性肿瘤中，如慢性髓细胞性白血病或非霍奇金淋巴瘤，专门设计用于靶向肿瘤特异性蛋白质的生物制剂和抗体已经彻底改变了治疗标准。在实体瘤中，靶向EGF或VEGF受体的新药现已获得批准，并正在进入临床实践，用于单独或与常规治疗方法联合治疗结肠癌、肺癌、肾癌和其他癌症。最近的数据表明，分子靶向治疗可能显示在头颈部鳞状细胞癌（HNSCC）患者的疗效。HNSCC患者通常对评价的生物制剂耐受良好，这些患者通常有多种合并症的负担，干扰常规全身治疗选择。因此，分子靶向治疗提供了新的治疗选择，即使是对于通常无法耐受化疗或放疗的重度预治疗和重病患者。两个最有前途和先进的策略是阻断生长因子为基础的细胞信号和干扰血管生成相关的途径。但是替代靶点的抑制剂，如Scr和蛋白酶体，已经在HNSCC患者的早期临床试验中进行了评估。
Targeted therapies have made their way into clinical practice during the past decade. They have caused a major impact on the survival of cancer patients in many areas of clinical oncology and hematology. Indeed, in some hematologic malignancies, such as chronic myelogenous leukemia or non-Hodgkin's lymphomas, biologicals and antibodies specifically designed to target tumour-specific proteins have revolutionized treatment standards. In solid tumours, new drugs targeting EGF- or VEGF- receptors are now approved and are entering clinical practise for treatment of colon, lung, kidney and other cancers, either alone or in combination with conventional treatment approaches. Recent data have now shown that molecular targeted therapy might display efficacy in patients with head and neck squamous cell carcinoma (HNSCC) as well. The evaluated biologicals are generally well tolerated from HNSCC patients, who usually have the burden of multiple co-morbidities that interfere with conventional systemic treatment options. Therefore, molecular targeted therapies offer new treatment options even for heavily pretreated and seriously ill patients usually unable to tolerate chemotherapy or radiation therapy. The two most promising and advanced strategies are the blockage of growth-factor based cellular signalling and interference with angiogenesis-related pathways. But inhibitors of alternative targets, such as Scr and proteasomes, have already been evaluated in early clinical trials with HNSCC patients.
登录
查看更多内容
DOI：
10.1186/1758-3284-1-36
发表时间：
2009-10-14
期刊：
Head & neck oncology
影响因子：
--
作者：
Goon PK;Stanley MA;Ebmeyer J;Steinsträsser L;Upile T;Jerjes W;Bernal-Sprekelsen M;Görner M;Sudhoff HH
通讯作者：
Sudhoff HH
影响因子：
3.6
作者：
Wheeler DL;Iida M;Kruser TJ;Nechrebecki MM;Dunn EF;Armstrong EA;Huang S;Harari PM
通讯作者：
Harari PM
影响因子：
51.1
作者：
Cohen, Ezra E. W.;Davis, Darren W.;Karrison, Theodore G.;Seiwert, Tanguy Y.;Wong, Stuart J.;Nattam, Sreenivasa;Kozloff, Mark F.;Clark, Joseph I.;Yan, Duen-Hwa;Liu, Wen;Pierce, Carolyn;Dancey, Janet E.;Stenson, Kerstin;Blair, Elizabeth;Dekker, Allison;Vokes, Everett E.
通讯作者：
Vokes, Everett E.
影响因子：
4.4
作者：
Bleeker, WK;van Bueren, JJL;Parren, PWHI
通讯作者：
Parren, PWHI
影响因子：
4.8
作者：
Iwase, Masayasu;Takaoka, Sayaka;Nagumo, Masao
通讯作者：
Nagumo, Masao